Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Jan;111(1):137–144. doi: 10.1111/j.1476-5381.1994.tb14035.x

Cardiovascular effects of GR117289, a novel angiotensin AT1 receptor antagonist.

A Hilditch 1, A A Hunt 1, C J Gardner 1, D J Twissell 1, J Polley 1, A Travers 1, G M Drew 1, D Middlemiss 1, B C Ross 1, M J Robertson 1
PMCID: PMC1910000  PMID: 8012689

Abstract

1. The effect of GR117289, an angiotensin AT1 receptor antagonist, on diastolic blood pressure (DBP) was determined in angiotensin-dependent and angiotensin-independent models of hypertension in rats. In addition, the antagonist profile of GR117289 at angiotensin AT1 receptors was determined in conscious renal hypertensive rats and conscious normotensive rats, dogs and marmosets. 2. Intra-arterial and oral administration of GR117289 (0.3-3 mg kg-1, i.a.; 1-10 mg kg-1, p.o.) to 6-day left renal artery ligated hypertensive (RALH) rats (DBP > 140 mmHg) produced significant, dose-related reductions in DBP with little apparent effect on heart rate (< 15%). The antihypertensive effect of GR117289 developed progressively over several hours and with some doses persisted for 24-48 h after administration. 3. Administration of GR117289 (1 mg kg-1, i.a.) on 5 consecutive days to RALH rats reduced DBP on each day. The antihypertensive effect of GR117289 was not cumulative as DBP had almost returned to base-line values, 24 h after administration of each dose. 4. A dose of GR117289 (3 mg kg-1, i.a.), which produced a substantial reduction in DBP (about 70 mmHg) in RALH rats, was administered to rats in which blood pressure was elevated either by unilateral renal artery clipping, sustained infusion of angiotensin II (AII), DOCA-salt administration or genetic inbreeding. GR117289 reduced DBP in rats in which the renin-angiotensin system was activated by renal artery clipping or AII infusion but had little effect in normotensive rats, DOCA-salt rats and SHR.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
137

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Asaad M. M., Antonaccio M. J. Vascular wall renin in spontaneously hypertensive rats. Potential relevance to hypertension maintenance and antihypertensive effect of captopril. Hypertension. 1982 Jul-Aug;4(4):487–493. doi: 10.1161/01.hyp.4.4.487. [DOI] [PubMed] [Google Scholar]
  2. Brooks D. P., Fredrickson T. A., Weinstock J., Ruffolo R. R., Jr, Edwards R. M., Gellai M. Antihypertensive activity of the non-peptide angiotensin II receptor antagonist, SK&F 108566, in rats and dogs. Naunyn Schmiedebergs Arch Pharmacol. 1992 Jun;345(6):673–678. doi: 10.1007/BF00164582. [DOI] [PubMed] [Google Scholar]
  3. Cangiano J. L., Rodríguez-Sargent C., Martínez-Maldonado M. Effects of antihypertensive treatment on systolic blood pressure and renin in experimental hypertension in rats. J Pharmacol Exp Ther. 1979 Feb;208(2):310–313. [PubMed] [Google Scholar]
  4. Cody R. J. Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure. A review. Drugs. 1984 Aug;28(2):144–169. doi: 10.2165/00003495-198428020-00004. [DOI] [PubMed] [Google Scholar]
  5. Edwards R. M., Aiyar N., Ohlstein E. H., Weidley E. F., Griffin E., Ezekiel M., Keenan R. M., Ruffolo R. R., Weinstock J. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther. 1992 Jan;260(1):175–181. [PubMed] [Google Scholar]
  6. Griffin S. A., Brown W. C., MacPherson F., McGrath J. C., Wilson V. G., Korsgaard N., Mulvany M. J., Lever A. F. Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension. 1991 May;17(5):626–635. doi: 10.1161/01.hyp.17.5.626. [DOI] [PubMed] [Google Scholar]
  7. Guo G. B., Abboud F. M. Angiotensin II attenuates baroreflex control of heart rate and sympathetic activity. Am J Physiol. 1984 Jan;246(1 Pt 2):H80–H89. doi: 10.1152/ajpheart.1984.246.1.H80. [DOI] [PubMed] [Google Scholar]
  8. Liu Y. J., Shankley N. P., Welsh N. J., Black J. W. Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action. Br J Pharmacol. 1992 Jun;106(2):233–241. doi: 10.1111/j.1476-5381.1992.tb14322.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. MacMahon S. Alcohol consumption and hypertension. Hypertension. 1987 Feb;9(2):111–121. doi: 10.1161/01.hyp.9.2.111. [DOI] [PubMed] [Google Scholar]
  10. Marks E. S., Bing R. F., Thurston H., Russell G. I., Swales J. D. Responsiveness to pressor agents in experimental renovascular and steroid hypertension. Effects of converting enzyme inhibitor and nephrectomy. Hypertension. 1982 Mar-Apr;4(2):238–244. doi: 10.1161/01.hyp.4.2.238. [DOI] [PubMed] [Google Scholar]
  11. O'Brien D. J., Chapman W. H., Rudd F. V., McRoberts J. W. Carotid artery loop method of blood pressure measurement in the dog. J Appl Physiol. 1971 Jan;30(1):161–163. doi: 10.1152/jappl.1971.30.1.161. [DOI] [PubMed] [Google Scholar]
  12. OKAMOTO K., AOKI K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J. 1963 Mar;27:282–293. doi: 10.1253/jcj.27.282. [DOI] [PubMed] [Google Scholar]
  13. Ohlstein E. H., Gellai M., Brooks D. P., Vickery L., Jugus J., Sulpizio A., Ruffolo R. R., Jr, Weinstock J., Edwards R. M. The antihypertensive effect of the angiotensin II receptor antagonist DuP 753 may not be due solely to angiotensin II receptor antagonism. J Pharmacol Exp Ther. 1992 Aug;262(2):595–601. [PubMed] [Google Scholar]
  14. POPOVIC V., POPOVIC P. Permanent cannulation of aorta and vena cava in rats and ground squirrels. J Appl Physiol. 1960 Jul;15:727–728. doi: 10.1152/jappl.1960.15.4.727. [DOI] [PubMed] [Google Scholar]
  15. Robertson M. J., Barnes J. C., Drew G. M., Clark K. L., Marshall F. H., Michel A., Middlemiss D., Ross B. C., Scopes D., Dowle M. D. Pharmacological profile of GR117289 in vitro: a novel, potent and specific non-peptide angiotensin AT1 receptor antagonist. Br J Pharmacol. 1992 Dec;107(4):1173–1180. doi: 10.1111/j.1476-5381.1992.tb13425.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Siegl P. K., Chang R. S., Mantlo N. B., Chakravarty P. K., Ondeyka D. L., Greenlee W. J., Patchett A. A., Sweet C. S., Lotti V. J. In vivo pharmacology of L-158,809, a new highly potent and selective nonpeptide angiotensin II receptor antagonist. J Pharmacol Exp Ther. 1992 Jul;262(1):139–144. [PubMed] [Google Scholar]
  17. Song K., Zhuo J., Allen A. M., Paxinos G., Mendelsohn F. A. Angiotensin II receptor subtypes in rat brain and peripheral tissues. Cardiology. 1991;79 (Suppl 1):45–54. doi: 10.1159/000174906. [DOI] [PubMed] [Google Scholar]
  18. Swales J. D. Arterial wall or plasma renin in hypertension? Clin Sci (Lond) 1979 Apr;56(4):293–298. doi: 10.1042/cs0560293. [DOI] [PubMed] [Google Scholar]
  19. Vari R. C., Zinn S., Verburg K. M., Freeman R. H. Renal nerves and the pathogenesis of angiotensin-induced hypertension. Hypertension. 1987 Apr;9(4):345–349. doi: 10.1161/01.hyp.9.4.345. [DOI] [PubMed] [Google Scholar]
  20. Wong P. C., Hart S. D., Chiu A. T., Herblin W. F., Carini D. J., Smith R. D., Wexler R. R., Timmermans P. B. Pharmacology of DuP 532, a selective and noncompetitive AT1 receptor antagonist. J Pharmacol Exp Ther. 1991 Nov;259(2):861–870. [PubMed] [Google Scholar]
  21. Wong P. C., Price W. A., Jr, Chiu A. T., Duncia J. V., Carini D. J., Wexler R. R., Johnson A. L., Timmermans P. B. Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent. J Pharmacol Exp Ther. 1990 Oct;255(1):211–217. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES